<DOC>
	<DOCNO>NCT02793908</DOCNO>
	<brief_summary>The aim study protocol compare efficacy subcutaneous progesterone ( 25 mg / day ; Pleyris , IBSA Institut Biochimique SA ) vaginal progesterone ( 90 mg / day ; Crinone , Merck Serono ) administer luteal phase term pelvic pain reduction patient grade I-II endometriosis / endometrioma &lt; 4 cm subject time intercourse COS/IUI cycle .</brief_summary>
	<brief_title>Subcutaneous Progesterone Supplementation Patients With Endometriosis</brief_title>
	<detailed_description>Patients grade I-II endometriosis / endometrioma &lt; 4 cm subject time intercourse COS/IUI cycle subject subcutaneous vaginal progesterone luteal phase supplementation time intercourses IUI cycle . The aim study protocol compare efficacy subcutaneous progesterone ( 25 mg / day ; Pleyris , IBSA Institut Biochimique SA ) vaginal progesterone ( 90 mg / day ; Crinone , Merck Serono ) administer luteal phase term pelvic pain reduction</detailed_description>
	<mesh_term>Endometriosis</mesh_term>
	<mesh_term>Progesterone</mesh_term>
	<criteria>Laparoscopic ultrasonographic diagnosis endometriosis grade III / endometrioma &lt; 4 cm ; Menstrual VAS score &gt; 5 cm last menstrual period progesterone treatment Infertility least 1 year Body Mass Index 19 30 kg / m2 Basal FSH serum &lt; 15 IU / ml Normal level serum prolactin Normal uterine cavity fallopian patency Previous ovarian surgery Endocrine disorder ( eg polycystic ovary syndrome , thyroid disease , hyperprolactinemia , hypogonadotropic hypogonadism ) Reduced ovarian reserve ( basal level FSH &gt; 15 IU / mL ) Acute chronic infectious state Chronic drug intake , alcohol , drug affect cognitive function , alertness / mood Psychiatric disorder Kidney liver diseases Male factor infertility</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>38 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Endometriosis</keyword>
	<keyword>Subcutaneous progesterone</keyword>
	<keyword>luteal phase</keyword>
</DOC>